Subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) offers the possibility of self-administration.
This is a pilot study of self-administration of DMPA-SC. Existing users of the intramuscular preparation (DMPA-IM) who wished to self-inject (n=64) were taught self-administration using DMPA-SC. The main outcome was the continuation rate of the method at 12 months compared to a control group of existing users of DMPA-IM (n=64) who continued to attend a clinic to receive the method. Women's satisfaction with the method and the proportion of self-injections given at correct time were also determined.
The 12-month discontinuation rate of the DMPA-SC group (12%) did not differ significantly from that of the DMPA-IM group (22%) (95% confidence intervals of 13%���33% and 6%���23% for DMPA-SC and DMPA-IM, respectively; p=.23). All self-injections were given within the appropriate interval. There was no significant difference in the proportion of women in either group who were satisfied with the method.
Self-administration of DMPA-SC for contraception is feasible and is associated with similar continuation rates and satisfaction to clinician-administered DMPA-IM.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Long-acting reversible methods of contraception. 2005[access date 10th June 2011])
- Opinions survey report no. 41. Contraception and sexual health. A report on research using the ONS Omnibus Survey produced by the Office for National Statistics on behalf of the Department of Health. Office for National Statistics, London2009[access date 7th July 2011])
- Contraceptive efficacy.in: Hatcher R.A. Trussel J. Stewart F. Nelson A. Cates W. Guest F. Kowal D. Contraceptive technology. 18th revised ed. Ardent Media, New York2004: 747-755
- Strategies to improve adherence and acceptability of hormonal methods of contraception.Cochrane Database Syst Rev. 2011; 4 ([Review]): CD004317
- Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera��.Contraception. 2004; 70: 11-18
- Contraceptive efficacy and safety of DMPA-SC.Contraception. 2004; 70: 269-275
- The acceptability of self-administration of subcutaneous Depo-Provera.Contraception. 2005; 72: 14-18
- Clinical Effectiveness Unit Guidance. Progestogen only injectable contraception.[access date 28th April 2011])
- Carstairs scores for Scottish postcode sectors from the 2001 Census Report; 2004.[access date 10 th June 2011])
- Selected practice recommendations for contraceptive use. 2nd ed. WHO, Department of Reproductive Health and Research, 2004[access date 7th july 2011])
- Self- administration with Uniject of the once-a-month injectable contraceptive Cyclofem.Contraception. 1997; 56: 301-304
- Self-injection of monthly combined hormonal contraceptive.Contraception. 2006; 73: 53-55
- Compliance with depot medroxyprogesterone acetate: a randomized controlled trial of intensive reminders.Am J Obstet Gynecol. 1995; 169: 583-585
- Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.Contraception. 2010; 82: 160-167
- Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.Contraception. 2009; 80: 7-17
- Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg.Contraception. 2006; 74: 234-238
- Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery.Clin Ther. 2000; 22: 1049-1067
- Safety and side effects of the insulin analogues.Expert Opinion on Drug Safety. 2006; 5: 131-143
- The GH Lipoatrophy Study Group. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.Eur J Endocrinol. 2009; 161: 533-540
- Lipolytic activity of progesterone and synthetic progestins on rat parametrial adipocytes in vitro.J Pharmacol Exp Ther. 1991; 258: 620-625
- First prescription of combined oral contraception. 2006[access date 7th July 2011])
- Provision of DMPA by community health workers: what the evidence shows.Contraception. 2011; 83: 495-503
Published online: November 14, 2011
Accepted: October 5, 2011
Received in revised form: September 15, 2011
Received: June 11, 2011
���Funding: This project was funded by an independent research grant from Sayana, Pfizer Inc., USA.
������Competing interests: There are no competing interests.
© 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.